Maël Heiblig

28PUBLICATIONS
361CO-AUTHORS
Gene and molecular therapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Nov 05, 2026
Tyrosine kinase inhibitors are associated with reduced AML transformation in systemic mastocytosis with myeloid neoplasm.

|Oct 27, 2026
Prognostic Impact of FLT3-ITD Allelic Ratio in AML Patients Treated With High-Dose Anthracycline and a FLT3 Inhibitor.

|Sep 04, 2026
Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

|Feb 27, 2026
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.

David B Beck, Maël Heiblig, Sinisa Savic

Pageof 5

Frequent Collaborators

6 joint publications

Emmanuelle Tavernier-Tardy

6 joint publications

Pierre-Yves Dumas

6 joint publications

Arsene Mekininan

5 joint publications

Christian Récher